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The trajectories of physical activity (PA) from midlife into old age and their associations with established and
novel cardiovascular disease (CVD) risk factors in later life remain unclear. This study examined associations
between 20-year nonoccupational PA trajectories and a range of CVD biomarkers at ages 60–79 years. We used
data from a sample of 3,331 men (mean baseline age = 50.2 ± 5.8 years) recruited in 1978–1980, with follow-up
after 12, 16, and 20 years, reporting habitual nonoccupational PA at each wave. At the 20-year follow-up, surviving
men attended a physical examination and provided a fasting blood sample. Group-based trajectory modeling was
used to identify trajectories. Adjusted regression analyses examined the association between trajectory-group
membership and several cardiometabolic, cardiac, and inﬂammatory markers at follow-up. Three distinct 20-year
trajectories were identiﬁed: low/decreasing (21.3%), light/stable (51.8%), and moderate/increasing (27.0%). Com-
pared with the low/decreasing group, membership in the light/stable and moderate/increasing trajectory groups
was associated with a more favorable cardiometabolic proﬁle and lower levels of inﬂammation and endothelial dys-
function. Although following a moderate-increasing PA trajectory was most favorable, more modest but sustained
doses of PA into old agemay be sufﬁcient to lower CVD risk.
aging; cardiovascular biomarkers; cardiovascular disease; inﬂammation; physical activity
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; GBTM, group-based trajectory
modeling; IL-6, interleukin-6; PA, physical activity; tPA, tissue plasminogen activator.
There is clear evidence that regular physical activity (PA) is
associated with a lower risk of cardiovascular disease (CVD)
morbidity and mortality (1, 2). The transition to old age is a
crucial life stage when future PA levels and the subsequent
risk of developing CVD in later life are determined (3, 4).
Previous studies examining the association between change
in PA and CVD biomarkers in old age are limited by relatively
short follow-up and few repeated measurements of PA, result-
ing in important PA ﬂuctuations being missed (5–10). Several
of these studies have shown that PA has cumulative effects
on CVD risk factors, with sustained high PA being most
strongly related with lower levels of established metabolic
risk factors, inﬂammation, endothelial dysfunction, and car-
diac injury in old age (5–7, 9, 10). Only a few prospective
studies with long-term follow-up have used more than 2 or 3
repeated measures of PA to examine associations with CVD
biomarkers in old age (11).
Existing studies typically use clinical cutpoints to collapse
PA data into a binary or ternary format to distinguish between
those who maintain or change their PA levels (9–11). This
conventional method for identifying trajectories assumes these
clinically relevant trajectory groups truly exist. By contrast,
group-based trajectory modeling (GBTM) is a data-driven
approach that has the ability “to identify rather than assume
distinctive groups of trajectories” (12, p. 139), thus describ-
ing the true underlying trajectories of behavior change over
time (13). Previous studies have used this technique to identify
trajectories of PA into old age (14–16), but to our knowledge
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it has not yet been used to examine associations with CVD
biomarkers. Longitudinal studies using more repeated mea-
sures of PA and data-driven techniques are required to under-
stand how patterns of PA into old age are associated with
established and novel CVD risk factors. The aim of this study
was therefore to explore associations between 20-year trajec-
tories of nonoccupational PA from midlife to old age, identi-
ﬁed using GBTM, and CVD biomarkers in old age in men
without preexisting CVD or diabetes at baseline.
METHODS
Participants
Data were drawn from the British Regional Heart Study, an
ongoing prospective cohort study following 7,735 men (aged
40–59 years at baseline) recruited from primary care practices
in 24 towns in Great Britain between 1978 and 1980 (17).
Men completed a lifestyle and medical history questionnaire
at baseline and at 12, 16, and 20 years, and they attended physi-
cal examinations at baseline and 20-year follow-up. Participants
provided informed written consent to the investigation. Ethical
approval was obtained from the National Research Ethics Service
Committee London.
Measures
CVD biomarkers. At the 20-year follow-up, men provided
a fasting blood sample, which was used for laboratory tests of
cholesterol (total, high-density lipoprotein, and low-density
lipoprotein), triglycerides, glycated hemoglobin, factor VIII,
plasma levels of tissue plasminogen activator (tPA) antigen,
D-dimer, von Willebrand factor, C-reactive protein (CRP),
interleukin-6 (IL-6), N-terminal pro-brain natriuretic peptide,
and high-sensitivity cardiac troponin T. Nurses measured waist
circumference, blood pressure, lung function (forced expira-
tory volume in 1 second), and height and weight, from which
bodymass index (BMI) was calculated (as weight (kg)/height
(m)2). Hypertension was deﬁned as a systolic blood pressure
of≥160mmHg, diastolic blood pressure≥100mmHg, or use
of antihypertensive medication (18). Further information on
measurement techniques is provided in Web Appendix 1
(available at https://academic.oup.com/aje).
Self-reported PA. At all follow-up examinations, partici-
pants reported their usual PA. Questions included time spent
on all forms of walking, recreational activities (such as recre-
ational walking, gardening, chores, and do-it-yourself activi-
ties), and sports/exercise. The same questions and response
optionswere administered at eachwave. Responseswere scored
based on the intensity and frequency of the activity (19, 20). For
example, making no journeys by foot was scored as 0 and >90
minutes/weekday was scored as 5. Scores were also heavily
weighted for vigorous activities. For example, playing sports
4–7 times a month was given a score of 8. Scores for each item
were summed together to give a total PA index. The original
scoring system has been reported in detail elsewhere (21). The
total PA index was then used to group men into 6 categories
(0–5); 0: inactive; 1: occasional (regular walking or recreational
activity only); 2: light (more frequent recreational activities,
sporting exercise less than once a week, or regular walking plus
some recreational activity); 3: moderate (cycling, very frequent
weekend recreational activities plus regular walking, or sport-
ing activity once a week); 4: moderately vigorous (sporting
activity at least once a week or frequent cycling, plus frequent
recreational activities or walking, or frequent sporting activi-
ties only); or 5: vigorous (very frequent sporting exercise or
frequent sporting exercise plus other recreational activities).
The 6-point total PA score used for the analysis has been valid-
ated against heart rate, forced expiratory volume in 1 second
(21), and device-measured PA (22).
Covariates. A range of sociodemographic characteristics,
health conditions, and lifestyle behaviors were reported in the
questionnaire. These included age, employment status (em-
ployed or not in employment), current or longest held occupa-
tion (manual or nonmanual), marital status (single, married, or
widowed/divorced), number of children (none or ≥1), doctor-
diagnosed health conditions (including arthritis, bronchitis, and
high blood pressure), other health problems (including breath-
lessness and chest pain on exertion), BMI (normal weight:
<25.0; or overweight/obese: ≥25.0), smoking status (current/
recent former-smoker or nonsmoker/long-term former-smoker
(>15 years)), alcohol consumption (none, occasional (<1
drink/week), light (1–15 drinks/week), moderate (16–42 drinks/
week), or heavy (>42 drinks/week)), region of residence
(Scotland, North, Midlands, or South), and weekly break-
fast cereal consumption (none, occasional (1–2 times/week),
or regular (>3 times/week)).Men also reported doctor-diagnosed
CVD events, including stroke (with symptoms lasting >24
hours), heart attack, myocardial infarction, coronary throm-
bosis and angina, and diabetes mellitus. In addition, medica-
tion use (warfarin, blood pressure-lowering medication, and
lipid-loweringmedication) was recorded at 20-year follow-up.
Statistical analysis
Identifying PA trajectory groups. GBTM was used to iden-
tify PA trajectories over the 4 time points inmenwithout stroke,
coronary heart disease, or diabetes at baseline. Analyses were
conducted using the Stata (StataCorp LLC, College Station,
Texas) TRAJ plugin (23), which applies ﬁnite mixture models
and maximum likelihood estimation to identify groups of indi-
viduals that follow similar patterns of behavior over time. To
identify the optimal number of trajectory groups, models with
2–5 groups were tested and compared using goodness-of-ﬁt cri-
teria. The best-ﬁtting model was selected based on highest (i.e.,
least negative) Bayesian information criterion, the log Bayes
factor (2 × Δ Bayesian information criterion), sufﬁcient trajec-
tory group sizes (i.e., at least 5% of participants in each trajec-
tory group), close agreement between the estimated probability
of group membership and the actual proportion of the sample
assigned to that group, posterior probabilities of >0.70, and
odds of correct classiﬁcation based on posterior probabilities
exceeding 5 (13). For each subject, the model provides the
probability of belonging to each of the identiﬁed trajectory
groups and assigns them to the trajectory group based on the
highest probability. Models for identifying these groups were
simultaneously adjusted for baseline age, occupational class,
marital status, number of children, region of residence, diagnosed
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health conditions (arthritis, bronchitis, and high blood pressure),
BMI, smoking status, alcohol consumption, and breakfast cereal
consumption as well as time-varying covariates, measured at
each wave, including number of CVD events and employment
status. To determine the shape of each trajectory, the level of the
polynomial function for each group was reduced, starting with
quadratic, until each growth parameter estimate was statistically
signiﬁcant (P < 0.05).
Regression analyses. Once the optimal shape and number
of trajectories were determined, descriptive characteristics and
CVD biomarkers were calculated for each trajectory group.
Linear regression was then used to estimate the association
between PA trajectory-group membership and CVD biomar-
kers at the 20-year follow-up. Because many of the men were
being treated for high blood pressure by the time of the 20-
year follow-up, logistic regression was used to estimate the
odds of having hypertension (including taking antihyperten-
sive medication) according to trajectory-group membership.
Regression models were adjusted for current age, smoking
status, alcohol consumption, waist circumference (except when
waist circumference was the outcome), occupational class,
region of residence, and use of lipid-lowering and antihyper-
tensive medication (except when hypertension was the out-
come). Models for tPA antigen, D-dimer, vonWillebrand factor,
and factor VIII were also adjusted for warfarin use. Insulin, gly-
cated hemoglobin, IL-6, CRP, D-dimer, N-terminal pro-brain
natriuretic peptide, high-sensitivity cardiac troponin T, and
glucose were log transformed because they were positively
skewed. Trends across trajectory groups were tested entering
the trajectory group variable as a continuous variable.
Additional and sensitivity analyses. To examine whether
current PA is a stronger predictor of CVD risk factors than
PA trajectories, we included both the PA trajectories and the
6-point total PA score at the 20-year follow-up in the models.
In addition, to explore whether GBTM yielded additional in-
sights compared with a more conventional approach of cate-
gorizing trajectories of PA, the trajectories were instead deﬁned
manually using a binary PA variable across 3 time points (base-
line, 12-year follow-up, and 20-year follow-up). At each of the
3 time points, men were classiﬁed as active (1) if they had at
least “light” activity or inactive (0) for inactive or occasional
activity. Men were allocated to 1 of 8 possible trajectories,
which are indicated by combinations of zeros and ones (1,
active; 0, inactive). For example, 0-0-0 represents inactivity
at all periods, while 1-0-0 indicates being active at baseline
only. Regression analyses were repeated with the manually
derived trajectories as the exposure. Further, to minimize the
effects of reverse causality, whereby those who were already
predisposed to develop CVD or diabetes during the trajectory
period go on to participate less in PA, regression models
were reﬁtted excluding men with CVD or diabetes at the 20-
year follow-up. To determine the effects of adiposity on the
estimates, regression models were reﬁtted without adjusting
for waist circumference. Finally, regression models were re-
ﬁtted after applying the probabilities of trajectory group
membership as weights, giving more weight to individuals
with a higher probability of belonging to a particular group.
The same adjustments were made in these additional models
as described in the main regression analyses.
RESULTS
Of the 7,735 men invited, men with<3 PA assessments (n =
2,752) or a diagnosis of stroke (n = 52), coronary heart disease
(n = 292), or diabetes (n = 156) at baseline were excluded. A
further 1,465 men were excluded due to incomplete biomarker
and covariate data, leaving a ﬁnal sample of 3,331 men (ﬂow
diagram,Web Figure 1). Compared with the ﬁnal sample, men
whowere excluded were less active at baseline (total PA score,
1.9 vs. 2.4; P < 0.001) and more likely to come from manual
occupations (71.4% vs. 52.4%; P < 0.001), be older (52.4 vs.
48.7 years; P < 0.001), and suffer from a range of health con-
ditions, such as breathlessness (12.2% vs. 2.8%; P < 0.001),
overweight/obesity (55.2% vs. 52.5%; P < 0.001), arthritis
(12.6% vs. 8.1%; P< 0.001), and bronchitis (23.8% vs. 13.9%,
P < 0.001).
As previously described in this cohort (14), 3 trajectory groups
of PA over the course of 20 years best described the data: low/
decreasing (21.3%), light/stable (51.8%), andmoderate/increasing
(27.0%) (see Figure 1). Results from the model selection pro-
cess are provided in Web Tables 1 and 2. Sociodemographic
characteristics, lifestyle behaviors, health status, and CVD
biomarkers are presented according to trajectory group in
Table 1.
Men in the low/decreasing group were older, less likely to
come from the south of England, and more likely to come from
manual occupations and be a recent or current smoker (P <
0.05). Regression analyses revealed that men in the light/stable
and moderate/increasing groups had a more favorable CVD
biomarker proﬁle than men in the low/decreasing group (see
Table 2). This included lower levels of insulin, glycated hemo-
globin, blood glucose, inﬂammatory markers (IL-6 and CRP),
and hemostatic factors (vonWillebrand factor, factor VIII, tPA
antigen, and D-dimer); a smaller waist circumference; and
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Figure 1. Physical activity trajectories from midlife to old age (n =
3,331; aged 58–81 years at follow-up), British Regional Heart Study,
1978–2000. The small dashes (with squares) represent the plotted
trajectory curve for the low/decreasing group (21.3%), the solid line
(with circles) represents the light/stable group (51.8%), and the large
dashes (with triangles) represent themoderate/increasing group (27.0%).
The plotted points show the mean physical activity score and 95% conﬁ-
dence intervals at each time point for each trajectory group.
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Table 1. Characteristics of 3,331Men at 20-Year Follow-up According to Physical Activity Trajectory Group, British Regional Heart Study, 1978–2000
Physical Activity Trajectory Group
Characteristic
Low/Decreasing (n = 708) Light/Stable (n = 1,725) Moderate/Increasing (n = 898) Total (n = 3,331)
No. % Mean (SD) Median(IQR) No. % Mean (SD)
Median
(IQR) No. % Mean (SD)
Median
(IQR) No. % Mean (SD)
Median
(IQR)
Age 69.4 (5.7) 68.5 (5.5) 67.7 (5.1) 68.5 (5.5)
Manual occupational class 428 60.5 966 56.0 350 39.0 1,744 52.4
Current/recent former-smoker 276 39.0 395 22.9 158 17.6 829 24.9
At least moderate alcohol
consumptiona
129 18.2 340 19.7 172 19.2 641 19.2
Resident in southern England 189 26.7 608 35.3 339 37.8 1,136 34.1
Taking antihypertensive
medication
298 42.1 520 30.1 215 23.9 1,033 31.0
Taking lipid-loweringmedication 54 7.6 113 6.6 63 7.0 230 6.9
Taking warfarin 26 3.7 50 2.9 18 2.0 94 2.8
HDL, mmol/L 1.3 (0.3) 1.3 (0.3) 1.4 (0.3) 1.3 (0.3)
LDL, mmol/L 3.8 (1.0) 4.0 (1.0) 3.9 (0.9) 3.9 (1.0)
Total cholesterol, mmol/L 5.9 (1.0) 6.0 (1.1) 6.0 (1.1) 6.0 (1.1)
Triglycerides, mmol/L 1.7 (1.2) 1.6 (1.0) 1.5 (1.0) 1.6 (1.0)
Glucose, mmol/L 1.7 (0.2) 1.7 (0.1) 1.7 (0.1) 1.7 (0.2)
Insulin, μ/mL 9.6 (8.0) 8.1 (6.0) 7.5 (5.3) 8.2 (6.4)
HbA1C, mmol/L 5.0 (0.8) 4.8 (0.7) 4.8 (0.7) 4.8 (0.8)
Hypertensionb 424 59.9 865 50.1 401 44.7 1,690 50.7
FEV1, L
c 234.5 (67.4) 260.2 (63.4) 276.5 (61.1) 259.1 (65.3)
Waist circumference, cm 99.9 (10.9) 96.5 (10.0) 95.3 (9.5) 96.9 (10.2)
IL-6, pg/mL 2.8 (2.5) 2.2 (1.8) 2.0 (1.5) 2.2 (1.9)
Factor VIII, IU/dL 138.2 (31.6) 130.8 (31.0) 127.5 (29.5) 131.5 (31.0)
vonWillebrand factor, IU/dL 147.9 (48.0) 137.5 (44.5) 133.4 (43.6) 138.6 (45.3)
tPA antigen, ng/mL 12.3 (4.9) 10.8 (4.2) 10.2 (4.0) 11.0 (4.4)
CRP, mg/L 2.3 (4.0) 1.4 (2.4) 1.2 (1.9) 1.5 (2.6)
D-dimer, ng/mL 86.0
(106.0)
75.0
(75.0)
68.0
(60.0)
74 (77.0)
Hs-TnT, pg/mL 12.6 (8.2) 11.3 (7.0) 11.5 (6.3) 11.6 (7.1)
NT-proBNP, pg/mLd 108.0
(208.0)
87.0
(133.0)
76.5
(108.0)
88.0
(141.0)
Abbreviations: CRP, c-reactive protein; FEV1, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; Hs-TnT, high-sensitivity cardiac troponin T;
IL-6, interleukin-6; IQR, interquartile range; LDL, low-density lipoprotein; NT-proBNP,N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator.
a Moderate alcohol consumption was deﬁned as 16–42 drinks/week.
b Hypertension was deﬁned as a systolic blood pressure of≥160mmHg, diastolic blood pressure≥100mmHg, or use of antihypertensive medication.
c Standardized for height bymultiplying FEV1 by the square of the mean population height (meters) divided by each participant’s height.
d Data weremissing for an additional 194men (n = 3,137).
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higher lung function and reduced odds of hypertension. Men
in the moderate/increasing group also had lower levels of tri-
glycerides. The magnitude of the associations was typically
stronger for the moderate/increasing group, and there was a
signiﬁcant linear trend across trajectory groups. In addition, the
light/stable group had signiﬁcantly lower levels of the cardiac
marker high-sensitivity cardiac troponin T in comparison with
the low/decreasing group.
Associations were also examined after including both PA
trajectory and current PA score (20-year follow-up) in the
models (Web Table 3). Inclusion of the current PA score
attenuated the association between trajectories of PA and
CVD biomarkers. Associations between trajectories and IL-6,
vonWillebrand factor, and D-dimer were largely attenuated
and no longer signiﬁcant. Associations with CRP were also
markedly attenuated to nonsigniﬁcance in the moderate increas-
ing group. Associations with metabolic markers were only mar-
ginally attenuated, many remaining signiﬁcant apart from insulin
and hypertension, which were borderline signiﬁcant. Additional
analyses using manually derived trajectories revealed similar as-
sociations with persistent activity proving optimal (Table 3). Per-
sistent inactivity (0-0-0) was most consistently associated with
the least favorable outcome. Associations with lung function,
IL-6, CRP, tPA antigen, and D-dimer were, however, largely
driven by recent PA. Additional analyses revealed that adjust-
ing for waist circumference resulted in the greatest reduction
in the estimates, suggesting that associations are largelymediated
by adiposity (see Web Table 4). Estimates were also attenuated
Table 2. Adjusted Associationa Between 20-Year Physical Activity Trajectories and Cardiovascular Markers at 20-Year Follow-up From Logistic
or Linear Regression Models (n = 3,331Men, Aged 58–81 Years at Follow-up), British Regional Heart Study, 1978–2000
OutcomeMeasure
Physical Activity Trajectory Groupb
P for TrendLight/Stable Moderate/Increasing
B Coefﬁcient 95%CI B Coefﬁcient 95%CI
Metabolic markers
HDL, mmol/Lc −0.03 −0.06, 0.00 0.01 −0.02, 0.05 0.304
LDL, mmol/Lc 0.09 0.00, 0.17 0.04 −0.06, 0.14 0.550
Total cholesterol, mmol/Lc 0.04 −0.05, 0.13 −0.01 −0.12, 0.10 0.798
Triglycerides, mmol/Lc −0.03 −0.06, 0.01 −0.06 −0.11,−0.02 0.005
Hypertensiond 0.78 0.64, 0.94 0.66 0.53, 0.81
Glucose, mmol/Lc −0.02 −0.04,−0.01 −0.03 −0.05,−0.01 0.005
Insulin, μ/mLc −0.08 −0.13,−0.03 −0.11 −0.17,−0.06 0.001
HbA1C, mmol/Lc,e −0.02 −0.03,−0.01 −0.02 −0.04,−0.01 0.014
FEV1, L
c,f 13.92 8.64, 19.19 22.21 16.09, 28.33 <0.001
Waist circumference, cmc −3.25 −4.13,−2.36 −4.22 −5.24,−3.19 <0.001
Inﬂammatory/hemostatic markers
IL-6, pg/mLc,e −0.12 −0.18,−0.07 −0.18 −0.24,−0.11 <0.001
CRP,mg/Lc,e −0.21 −0.30,−0.11 −0.27 −0.38,−0.17 <0.001
Factor VIII, IU/dLc,g −5.01 −7.72,−2.31 −5.72 −8.86,−2.58 0.001
vonWillebrand factor, IU/dLc,g −5.73 −9.65,−1.81 −6.42 −10.97,−1.88 0.009
tPA antigen, ng/mLc,g −0.69 −1.05,−0.33 −1.05 −1.46,−0.63 <0.001
D-dimer, ng/mLc,e,g −0.10 −0.16,−0.03 −0.11 −0.19,−0.03 0.010
Cardiacmarkers
Hs-TnT, pg/mLc,e −0.07 −0.11,−0.03 −0.03 −0.08, 0.02 0.303
NT-proBNP, pg/mLc,e,h −0.07 −0.17, 0.02 −0.06 −0.17, 0.06 0.381
Abbreviations: CI, conﬁdence interval; CRP, c-reactive protein; FEV1, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; HDL,
high-density lipoprotein; Hs-TnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-
brain natriuretic peptide; tPA, tissue plasminogen activator.
a All models adjusted for age, occupational class, region of residence, smoking status, alcohol consumption, waist circumference (except where
waist circumference was the outcome, whenmodels adjusted for all other factors except waist circumference), and lipid-lowering medication.
b Low/decreasing group served as the reference group.
c Additionally adjusted for blood pressure-loweringmedication.
d Presented as an odds ratio and 95% conﬁdence interval. Hypertension was deﬁned as a systolic blood pressure of ≥160 mm Hg, diastolic
blood pressure≥100mmHg, or use of antihypertensivemedication.
e Log transformed.
f FEV1 was standardized for height by multiplying FEV1 by the square of the mean population height (meters) divided by each participant’s
height.
g Additionally adjusted for warfarin.
h Data were missing for an additional 194men (n = 3,137).
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Table 3. Adjusted Associationa Between 20-Year Subjectively Determined Physical Activity Trajectories and Cardiovascular Markers at 20-Year Follow-up From Logistic or Linear Regression
Models in MenWithout Preexisting CVD and Diabetes (n = 3,079, Aged 58–81 Years at Follow-up), British Regional Heart Study, 1978–2000
OutcomeMeasure
Physical Activity Trajectory Groupb,c
0-1-1 1-0-1 0-0-1 1-1-0 0-1-0 1-0-0 0-0-0
(n = 394; 12.8%) (n = 198; 6.4%) (n = 161; 5.2%) (n = 270; 8.8%) (n = 182; 5.9%) (n = 221; 7.2%) (n = 308; 10.0%)
B Coefﬁcient 95%CI B Coefﬁcient 95%CI B Coefﬁcient 95%CI B Coefﬁcient 95%CI B Coefﬁcient 95%CI B Coefﬁcient 95%CI B Coefﬁcient 95%CI
Metabolic markers
HDL, mmol/Ld −0.02 −0.06, 0.01 0.03 −0.02, 0.08 −0.01 −0.06, 0.04 −0.02 −0.06, 0.02 0.02 −0.03, 0.07 0.03 −0.01, 0.08 −0.03 −0.06, 0.01
LDL, mmol/Ld 0.05 −0.05, 0.16 0.04 −0.10, 0.18 0.02 −0.14, 0.17 0.00 −0.13, 0.12 −0.14 −0.29, 0.01 −0.03 −0.16, 0.11 −0.06 −0.18, 0.06
Total cholesterol, mmol/Ld 0.10 −0.02, 0.21 0.06 −0.09, 0.22 −0.01 −0.18, 0.17 0.01 −0.13, 0.14 −0.14 −0.31, 0.02 0.01 −0.14, 0.16 0.01 −0.12, 0.14
Triglycerides, mmol/Ld 0.07 0.02, 0.12 0.00 −0.06, 0.07 −0.02 −0.09, 0.05 0.03 −0.03, 0.09 −0.02 −0.08, 0.05 −0.02 −0.08, 0.05 0.10 0.05, 0.15
Hypertensione 1.15 0.91, 1.46 1.43 1.05, 1.95 1.27 0.90, 1.79 1.44 1.09, 1.89 1.27 0.91, 1.76 1.40 1.03, 1.89 1.52 1.17, 1.98
Glucose, mmol/Ld 0.01 −0.01, 0.03 0.01 −0.02, 0.04 0.03 0.00, 0.06 0.02 0.00, 0.04 0.05 0.02, 0.08 0.01 −0.02, 0.03 0.03 0.01, 0.05
Insulin, μ/mLd 0.06 0.00, 0.12 0.09 0.01, 0.17 0.04 −0.05, 0.13 0.07 0.00, 0.14 0.09 0.01, 0.18 0.02 −0.05, 0.09 0.16 0.09, 0.22
HbA1C, mmol/Ld,f 0.00 −0.01, 0.02 0.00 −0.02, 0.02 0.01 −0.01, 0.04 0.00 −0.02, 0.02 0.02 −0.01, 0.04 0.00 −0.02, 0.03 0.02 0.00, 0.04
FEV1, L
d,g 1.20 −5.39, 7.79 −5.15 −13.90, 3.59 −4.83 −14.47, 4.82 −12.19 −19.88,−4.50 −15.15 −24.28,−6.01 −12.63 −21.05,−4.20 −11.72 −19.09,−4.36
Waist circumference, cmd 0.55 −0.57, 1.67 1.15 −0.33, 2.64 2.84 1.20, 4.47 1.24 −0.06, 2.55 2.07 0.52, 3.62 4.20 2.77, 5.62 3.27 2.03, 4.52
Inﬂammatory/hemostatic markers
IL-6, pg/mld,f 0.03 −0.04, 0.10 −0.07 −0.17, 0.02 −0.01 −0.11, 0.10 0.16 0.08, 0.24 0.11 0.01, 0.21 0.13 0.04, 0.22 0.13 0.05, 0.21
CRP, mg/Ld,f −0.07 −0.18, 0.05 0.09 −0.07, 0.24 0.12 −0.05, 0.29 0.15 0.01, 0.28 0.08 −0.08, 0.24 0.29 0.14, 0.44 0.15 0.02, 0.28
Factor VIII, IU/dLd,h 0.80 −2.58, 4.18 −0.94 −5.42, 3.55 1.16 −3.79, 6.11 2.85 −1.09, 6.80 3.25 −1.44, 7.94 2.37 −1.95, 6.70 3.17 −0.61, 6.95
vonWillebrand factor, IU/dLd,h 2.11 −2.81, 7.02 0.22 −6.30, 6.74 2.57 −4.62, 9.76 4.71 −1.02, 10.45 4.10 −2.71, 10.92 6.94 0.65, 13.22 3.46 −2.03, 8.96
tPA antigen, ng/mLd,h 0.19 −0.26, 0.64 0.23 −0.37, 0.82 −0.26 −0.92, 0.40 0.53 0.01, 1.06 0.92 0.30, 1.54 0.46 −0.12, 1.03 1.03 0.52, 1.53
D-dimer, ng/mLd,f,h −0.04 −0.13, 0.04 −0.08 −0.19, 0.04 −0.10 −0.23, 0.02 0.09 −0.01, 0.19 0.07 −0.05, 0.19 0.12 0.02, 0.23 0.08 −0.02, 0.17
Cardiac markers
Hs-TnT, pg/mLd,f −0.03 −0.08, 0.02 0.02 −0.04, 0.09 −0.03 −0.11, 0.04 0.02 −0.04, 0.08 0.01 −0.06, 0.08 0.02 −0.05, 0.09 0.01 −0.04, 0.07
NT-proBNP, pg/mLd,f,i −0.06 −0.18, 0.06 0.07 −0.10, 0.23 −0.02 −0.20, 0.16 0.14 0.00, 0.28 0.11 −0.06, 0.28 0.18 0.02, 0.34 −0.05 −0.19, 0.08
Abbreviations: CI, conﬁdence interval; CRP, c-reactive protein; FEV1, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; Hs-TnT, high-
sensitivity cardiac troponin T; IL-6, interleukin-6; LDL, low-density lipoprotein; NT-proBNP,N-terminal pro-brain natriuretic peptide; tPA, tissue plasminogen activator.
a All models adjusted for age, occupational class, region of residence, smoking status, alcohol consumption and waist circumference (where waist circumference was the outcome models
adjusted for all other factors except waist circumference), and lipid-lowering medication.
b At each of the 3 time points, men were classiﬁed as active (1) if they had at least “light” activity or inactive (0) for inactive or occasional activity. Menwere allocated to 1 of 8 possible trajectories,
which are indicated by combinations of zeros and ones (1, active; 0, inactive). For example, (0-0-0) represents inactivity at all periods, while (1-0-0) indicates being active at baseline only.
c The 1-1-1 group (persistently active; n = 1,345, 43.7%) served as the reference group.
d Additionally adjusted for blood pressure-lowering medication.
e Presented as an odds ratio and 95% conﬁdence interval. Hypertension was deﬁned as a systolic blood pressure of≥160mmHg, diastolic blood pressure≥100mmHg, or use of antihyperten-
sive medication.
f Log transformed.
g FEV1 was standardized for height bymultiplying FEV1 by the square of the mean population height (meters) divided by each participant’s height.
h Additionally adjusted for warfarin.
i Data weremissing for an additional 178men (n = 2,901).
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after excluding men with stroke, coronary heart disease, and
diabetes at the 20-year follow-up, but associations with insu-
lin, lung function, waist circumference, IL-6, CRP, tPA antigen,
and high-sensitivity cardiac troponin T remained signiﬁcant
(Web Table 5). Conclusions were not changed when analyses
were weighted according to trajectory-group probabilities (data
not shown).
DISCUSSION
The present study found that the most active trajectory
(moderate/increasing) frommidlife to old age was most favor-
ably associated with CVD biomarkers in old age. However,
even more modest but persistent PA (light/stable) yielded sig-
niﬁcant health beneﬁt. Sustained light volumes of PA into old
age, including occasional sporting exercise ormoderate amounts
of walking combined with some gardening/do-it-yourself pro-
jects, may be sufﬁcient to reduce a range of CVD risk factors.
To our knowledge, this is the ﬁrst study to explore associa-
tions between trajectories of PA and CVD risk factors using
GBTM. Our ﬁndings are not directly comparable with pre-
vious studies using more conventional approaches for iden-
tifying trajectories due to the different groups that we have
identiﬁed using GBTM. Previous studies categorizing groups
manually using a clinically meaningful cutpoint suggest that
individuals who become active in old age present a better
CVD biomarker proﬁle than those who remain or become
inactive, including an improved lipid proﬁle and glucose toler-
ance and lower levels of inﬂammatory and hemostatic markers
and N-terminal pro-brain natriuretic peptide (7–11, 24). How-
ever, using GBTM, we did not observe groups of individuals
who made clear shifts from low to high PA or vice versa.
Instead our ﬁndings suggest that PA in old age is largely dic-
tated by PA in midlife or earlier, indicating that early engage-
ment is crucial for lowering CVD risk factors in old age.
Generally, our ﬁndings are consistent with evidence that sus-
tained higher levels of PA are associated with the most optimal
CVD biomarker proﬁle.
Moreover, due to the more subjective approaches that are
often adopted for classifying trajectories, usually involving
collapsing PA data into a small number of categories, the dose
or volume of PA required across the life course to achieve ben-
eﬁt remains unclear. Given that few older adults consistently
meet or start meeting current PA guidelines (7.9% and 4.9%,
respectively) (25), it is important to understand whether lower
doses of PA are sufﬁcient in old age. Although the guidelines
recommend that adults should spend 150 minutes per week
doing moderate-to-vigorous physical activity (MVPA), evi-
dence that lower doses might be sufﬁcient to achieve health
beneﬁts has been building (26). Previous results from this
cohort using self-reported measures of PA have shown that
light amounts of self-reported PA measured at a single time
point were associated with lower levels of inﬂammatory and
hemostatic markers, N-terminal pro-brain natriuretic peptide,
and risk of coronary heart disease (10). The present study
builds on this evidence by showing that sustaining a light dose of
PA frommidlife to old age can be sufﬁcient to achieve such ben-
eﬁts, which is perhaps a more feasible target for inactive middle-
aged and older adults. There is also accumulating evidence that
lower intensities of activitymight be sufﬁcient to achieve beneﬁt.
Indeed, it has been shown that device-measured light-intensity
PA is associated with lower levels of cardiac markers and
reducedmortality risks, independent ofMVPA (27–29).
In models that included both the trajectory and current PA,
the trajectory remained signiﬁcantly associatedwith themajority
of the metabolic markers. Long-term persistent PA also proved
optimal for metabolic outcomes when trajectories were classi-
ﬁed using a conventional approach. Together these results sug-
gest that sustained PA may have cumulative beneﬁts to
metabolic health, making it clinically important to consider
PA history. These ﬁndings are consistent with a 5-year pro-
spective study in older US adults that found that consistently
meeting PA guidelines through walking was associated with
the lowest risk of developing metabolic risk factors (24). One
important pathway that could explain the metabolic responses
to chronic PA is changes to body composition. Regular sus-
tained PA is associated with reductions in visceral fat, increases
in skeletal muscle mass, and improved metabolic efﬁciency of
muscle (30).
In contrast to the metabolic markers, associations with
inﬂammatory and hemostatic biomarkers were largely driven
by recent PA rather than long-term engagement. Intervention
studies have also demonstrated that reductions in inﬂamma-
tion can be achieved from fairly short-term increases in PA
(31). Observations from the 1946 British Birth Cohort Study
suggest that more frequent participation in leisure-time PA
across adulthood (ages 36–64 years) is associated with lower
CRP, IL-6, and tPA antigen in men at ages 60–64 years (11).
Our data suggest that such beneﬁts might be achieved by sus-
taining light volumes of PA across adulthood; however, the
cumulative effect of PA across the life course might be more
important for preserving metabolic health than for reducing
inﬂammation and endothelial dysfunction. Although both of
these studies are in older British men, they are not directly
comparable given the differences in how PA and trajectories of
PA were deﬁned. Additional prospective studies with repeated
measures of PA are required to fully understand whether the ef-
fects of PA on biomarkers are due to long-term engagement or
participation at speciﬁc life stages.
Many of the observed associations were substantially, but
not completely, attenuated by adiposity. Adiposity is an impor-
tant pathway explaining the relationship between PA and CVD
biomarkers, but there are other pathways involved. Other stud-
ies have also shown that associations between PA and CVD
risk factors persist after controlling for adiposity (7, 9, 11). As-
sociations were also largely attenuated when men who devel-
oped CVD over the 20-year follow-up were excluded, but
many remained signiﬁcant, strengthening the likelihood of a
causal link between long-term PA from midlife and CVD risk
factors in old age.
The key strength of this study is the long-term follow-up,
including repeated PA measurements over an understudied
period of the life course. Follow-up from midlife, a period
before many risk factors for CVD present themselves, reduces
the possibility of reverse causation. Unfortunately, we were
unable to capture early-life PA, which may already have inﬂu-
enced CVD risk factors in later life. Another strength is the
data-driven approach to identify trajectories. This enabled us
to identify the unobserved patterns of PA, which could not
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have been described using conventional methods, and more
precisely determine the optimal long-term patterns of PA for
CVD risk. Another advantage of GBTM over conventional
methods is that it can incorporate time-stable and time-varying
covariates in the modeling process, allowing the shapes of
each trajectory to vary according to variables beyond age or
time. This results in more accurate descriptions of the trajecto-
ries and thus more reliable estimates of the associations with
outcomes of interest.
A notable limitation is the use of self-reported PA, which is
prone to recall bias. Device-measured PA may be more sensi-
tive to changes in PA andmore accurately estimate the volume
and intensity required to reduce CVD risk factors (32). Never-
theless, the PA score has been validated against heart rate,
forced expiratory volume in 1 second, and device-measured
PA (22). In addition, it is possible that the early development
of chronic conditions, before midlife, may have already inﬂu-
enced PA trajectories; thus we cannot rule out reverse causa-
tion. Further, subject attrition may have biased our results given
that men who dropped out of the study were less active and
more likely to have a range of health conditions at baseline.
However, we previously showed that these trajectories are
comparable when men with only 1 PAmeasurement were also
included (14). Finally, it is important to note that our ﬁndings
are only in men and may not be generalizable to women and
nonwhite ethnic groups.
In conclusion, trajectories of PA from midlife to old age
were associated with established and novel CVD risk factors.
Although following a moderate/increasing trajectory proved
optimal, a light/stable trajectory yielded similar beneﬁts. This
supports the argument that even fairly modest but sustained
volumes of PA into old age may protect against CVD. This is
important given that higher doses and intensities of PA are
more challenging in aging adults.
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